

## **Comparative Effectiveness and Safety of Abaloparatide a Osteoporosis in Postmenopausal Women: A Systemati** Yu Ren, PhD Candidate<sup>1</sup>, Ami Vyas, PhI <sup>1</sup>Department of Pharmacy Practice & Clinical Research, College of Pharmacy, Ur

## Background


- Osteoporosis is characterized by loss of bone mass, which increases the risk of fractures<sup>[1]</sup>.
- Age-adjusted prevalence of osteoporosis aged 50 and over was 12.6%, the prevalence in women is higher than that in men (19.6% vs 4.4%)<sup>[2]</sup>, largely due to menopause serving as a significant risk factor.
- Abaloparatide, a novel synthetic analogue of human parathyroid hormone-related peptide, appears to have better efficacy and safety than teriparatide<sup>[3]</sup>, which has the same mechanism of action.
- To date, no systematic review and meta-analysis is conducted to examine the effectiveness and safety of abaloparatide compared teriparatide.

## Objective

• To conduct a systematic review and meta-analysis to evaluate the effectiveness and safety of abaloparatide compared to teriparatide in treating osteoporosis in postmenopausal women.

## Methods

- PubMed, Embase, Cochorane library, and www.clinicaltrials.gov databases were searched from database inception to April 2023.
- Review Manager 5.4 was applied to perform the meta-analysis and random-effects models were used to derive pooled estimates.
- Randomized controlled clinical trials and observational studies were assessed using the Cochrane Risk of Bias Tool and the Newcastle-Ottawa Scale, respectively.



Description       Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>			Results	7892
Description       Description <thdescription< th=""> <thdescription< th=""></thdescription<></thdescription<>	Non-verte	bral fracture	25	
Analog 22 - 01190 007/2 94.6% 0.79 [0.43, 1.03]     Milev2016 - 0.2362 0.3101 6.4% 0.79 [0.43, 1.43]     Jos C)	Study or Subgroup log[	Hazard Ratio] SF Wei		Hazard Ra M. Random (
<pre>genety: Tau"= 0.00; ChP=0.14; df=1 (P=0.71); P=0% Toverall effect Z=1.70 (P=0.09)  Alajor adverse cardiovascular events (MACE)  Alajor adverse cardiovascular events  Alajor adverse cardiovascular events (MACE)  Alajor adverse cardiovascular events (MACE)  Alajor adverse cardiovascular events in postmenopausal woll teoporosis.  Alajor adverse and teriparatide, further resea eded to evaluate the comparative effective or treatments on other important outcome  Alajor adverse adverse adverse adverse on other important outcome  Alajor adverse cardiovascular events in postmenopausal woll teoporosis.  Alagor adverse adverse adverse adverse adverse effective or treatments on other important outcome  Alagor adverse adverse adverse adverse adverse effective or treatments on other important outcome  Alagor adverse adverse adverse adverse adverse adverse adverse adverse adverse or treatments on other important outcome  Alagor adverse adverse adverse adverse adverse adverse adverse or treatments on other important outcome  Alagor adverse adverse adverse adverse adverse adverse adverse adverse or treatments on other important outcome  Alagor adverse or treatments on other important outcome  Alagor adverse ad</pre>	Cosman2022 Paul D Miller2016	-0.1159 0.0742 94.0	6% 0.89 [0.77, 1.03]	
roveral effect 2 = 1.70 (P = 0.09) Favours (experimental) lajor adverse cardiovascular events (MACE) Subgroup togHazard Ratiol SE Weight M. Random, 95% CI M. Random an2022 0.004 0.01 98.2% 1.00 (0.84, 1.19) out out out 0.11 0.867 0.18% 0.96 (0.23, 3.15) prevents Tau <sup>2</sup> = 0.00, Chi <sup>2</sup> = 0.06, df = 1 (P = 0.81); P = 0% wereal effect Z = 0.01 (P = 0.96) roveral effect Z = 0.01 (P = 0.96) se characterized and heart fail roveral effect Z = 0.01 (P = 0.96) se characterized and heart fail roveral effect Z = 0.01 (P = 0.96) se characterized and heart fail roveral effect Z = 0.01 (P = 0.96) se characterized and heart fail roveral effect Z = 0.01 (P = 0.96) se characterized and heart fail roveral effect Z = 0.78 (P = 0.44) se findings suggest that abaloparatide is not control of the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective o treatments on other important outcome	<b>otal (95% CI)</b> Heterogeneity: Tau² = 0.00;	그리는 것과 - 것같은 것이라는 것이라는 것이라 것이 같은 것은 것이라.	·⊫=0%	•
Hazard Ratio Subgroup log(Hazard Ratio) SE Weight IV. Random, 95% CI N. Random an2022 0.001 0.01 0.031 98.2% 1.00 [0.84, 1.19] out of the second	밖에는 아이에 많아 요구하는 것이 아이에 가지 않는 것이 아이들이 많다.	승규님 사람이 있는 그 것 같은 것 같아		J.01 0.1 1 Favours [experimental] Fa
composite outcome of MACE and heart fail Hazard Ratio Hazard Ratio Hazard Hazard Ratio Hazard H	o <mark>tal (95% CI)</mark> eterogeneity: Tau <sup>z</sup> = 0.00; C	<b>100.</b> Chi <sup>z</sup> = 0.06, df = 1 (P = 0.81); I <sup>z</sup>	0% 1.00 [0.84, 1.19] °= 0% ⊢	
Hard Ratio N. Random, 95% CI N. Random, 95% CI Digitizard Ratio Digitizard	est for overall effect: Z = 0.0	1 (P = 0.99)	10	Favours [experimental] Fav
or Stubgroup       log[Hazard Ratio]       SE       Weight       IV, Random, 95% CI       IV, Random, 2020         Cosman2020       -0.0607       0.0628       99.1%       1.05 [0.93, 1.19]       1.05	A composi	te outcome		
e findings suggest that abaloparatide is not inficantly different from teriparatide in red rebrai fractures and safety with regard to rdiovascular events in postmenopausal wor teoporosis.	<u>Study or Subgroup log</u> Cosman2022		eight IV, Random, 95% Cl 9.1% 1.05 [0.93, 1.19]	IV, Random, 1
e findings suggest that abaloparatide is not inificantly different from teriparatide in red rtebral fractures and safety with regard to rdiovascular events in postmenopausal wor teoporosis. He to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective to treatments on other important outcome	elicia Cosman2020 <b>otal (95% CI)</b>			•
e findings suggest that abaloparatide is not inificantly different from teriparatide in red rtebral fractures and safety with regard to rdiovascular events in postmenopausal wor teoporosis. The to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective to treatments on other important outcome	19월 - 28일에 있는		I <sup>z</sup> = 0%	0.01 0.1 1 Favours (experimental) Fa
e findings suggest that abaloparatide is not inificantly different from teriparatide in red rtebral fractures and safety with regard to rdiovascular events in postmenopausal wor teoporosis. The to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective to treatments on other important outcome			•	
inificantly different from teriparatide in red rtebral fractures and safety with regard to rdiovascular events in postmenopausal wor teoporosis. In to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective o treatments on other important outcome		CC	onclusio	
rtebral fractures and safety with regard to rdiovascular events in postmenopausal wor teoporosis. In to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective to treatments on other important outcome			•	
rdiovascular events in postmenopausal wor teoporosis. Ie to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective to treatments on other important outcome	U	•	•	
teoporosis. Ie to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective o treatments on other important outcome			•	6
ie to the lack of head-to-head studies comp aloparatide and teriparatide, further resea eded to evaluate the comparative effective to treatments on other important outcome			n postmen	opausai wom
aloparatide and teriparatide, further resea eded to evaluate the comparative effective o treatments on other important outcome	osteoporos	SIS.		
eded to evaluate the comparative effective to treatments on other important outcome	Due to the	lack of head	d-to-head s	tudies compa
o treatments on other important outcome	abaloparat	ide and teri	paratide, fu	rther resear
•	needed to	evaluate the	e comparati	ve effectiver
	two treatm	nents on oth	er importa	nt outcomes
rtebral and hip fractures.	needed to	evaluate the nents on oth	e comparati er importai	ive effec <sup>.</sup>

Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med, 2023. 176(2): p. 182-195. [2]. Sarafrazi, N., E.A. Wambogo and J.A. Shepherd, Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018.

NCHS Data Brief, 2021(405): p. 1-8. [3]. Miller P D, Hattersley G, Riis B J, et al. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial[J]. JAMA, 2016,316(7):722-733.



